Humanity

Thanks Michael. Happy to schedule a call if you'd like to dig in more, as sounds like you are much like many of our existing investors, so appreciate the feedback. As mentioned below, we are currently undertaking a CPA review as part of the Wefunder process and thus our financials will be added to the page once complete. As mentioned below, I can add a summary of our financial forecasts and some of unit economics also, at the same time.

Hi Jeremy, Thanks for your questions! The freemium subscription flywheel, once you get both the unit economics and viral coefficient right, is what propels the business model at that level of scale. For example, when my awesome co-founder Michael Geer was running operations at AnchorFree, they successfully grew subscription revenues to $300m a year, by scaling up both b2c and b2b channels in this way. We intend to do the same and thus a combination of B2B traction with enterprises (especially once our platform becomes self serve) and by getting the social engagement and one-to-many feedback loops humming, we will be able to unlock that level of growth and more. The only question is how long it takes to reach that inflection point. We are getting closer all the time, and that's the main focus for early 2024. I hope that helps!

Hi Brian, thanks for your questions! 1. We have already reached our first fundraising goal, which is $500k via Wefunder and c. $2.5m in total on the same terms. We've decided to keep the option open for people to invest for the coming weeks as we see it as a great way to foster brand advocacy and a key part of our mission to extend the impact beyond the privileged few. The likely cap will be a few hundred k more. 2. This is based on the number of ratings and reviews and rating level in the App Store. If you search for "Longevity" apps in the App Store, you will see that we are by far the leading app in the category. I hope that helps!

Thanks for the questions and kind words, Brian! 1. We currently are live with a Premium subscription which has an average cost of $50 per year and only sold annually. We will be going live with a higher Pro subscription level (includes blood result analysis from our new blood model just published in Nature!) that will most likely retail at an average of $120 per year and again sold annually. 2. The 4 main components of Biological Age measure are the "digital markers" of movement pattern and heart rate pattern (both live in the app now already) and we will then release blood analyte analysis in Pro (details above) and then next year we will release DNA Methylation analysis (most likely included in Pioneer subscription plan).

Hi Deng, We plan to launch on Android next year. Best, Pete

Hi Dan, apologies - I only just saw your questions and appreciate it's now too late. Happy to jump on a call if you'd like to revisit. Just noted that your summary compared us to hardware devices which we are not competing against. Let me know if you'd still like to set up a call.

For the benefit of others, I can answer your questions above: 1) We are offering Premium and Pro (includes blood aging) licences, Humanity for Teams / Enterprise, and have Biological Age APIs. Each offering has a number of features and benefits which can be customised to the client and use case need. Multiple use cases: Offer to customers to inprove their health over time or between visits, adding aging measures to other health markers, reducing absenteesim and increasing team wellbeing and productivity, enhancing diagnostic offerings, creating more stickiness, retention and upgrade benefits or reasons to subscribe on third party platforms / adding more premium benefits to existing offerings. The list goes on. Pricing is on a per user fee depending on offering with discounts on volume etc. 2. Over 30 of them. 3. We did a rolling close on this round as had a number of angel investors and funds that wanted to come in over the past few months. Funds have been invested mainly in R&D activities including the Blood Aging model which is now successfully published in Nature. We now have runway until the end of 2024 but this will continually extend as we scale up revenues this year. 4. It is. Most apps and devices are focused on fitness or specific niches like meditation. Humanity is based on scientifically basked models for measuring your biological age and rate of aging, combined with a best-in-class UI/UX that has proven behaviour change and market leading engagement, retention and conversion metrics. We are agnostic to wearable and actually complement / amplify the value of wearables including the Apple Watch, Oura, Whoop and other devices. We are also by far the leading longevity app on the app store by number of reviews and ratings and by various external measures. What also differentiates us is our proven track record, investment backing, science advisory board, team, metrics and positioning. Watch this space, as we scale up and prove this out.

Hi Jeremy, Great question! Yes of course. We see generative AI playing an increasingly bigger role in the app personalization experience in iterations to come. Watch this space!..

Hi Randon, Thanks for the questions.. We see Apple (Health and Watch) to be enablers and for Apple to be a strong partner as we scale. There is always competitive risk but based on our perspective, our approach and offering is highly complimentary to Apple's strategy as Humanity drives more engagement (and purchases) of Apple products and showcases their technology. Genotyping and DNA methylation profiling will be offered as a premium package we are dubbing "Pioneer". Details are still to be finalised as it's not the current priority but it will likely involve partnership with 3rd party labs and other key players in the ecosystem. The cost is yet to be determined but we have modelled it out to be competitively priced to attract as much adoption as possible. In regards to your last questions, it technically could but this is not the focus for now. We are primarily focused on the ostensibly healthy population as a wellness product, getting to "consumer-grade" for the mainstream marker. However, our intention is to become more "clinical-grade" in future as we demonstrate the impact of our offering in broader use cases to reduce disease risk in the first instance. I hope that helps answer your questions!

Hi Aryana! Thanks for your message. I'd be happy to schedule a call. I'm pretty stacked this week as in Taipei and Lisbon next week but will ping you my calendar via LinkedIn and hopefully can find a time to chat late next week. I can also ping you if I find myself free out of hours and in front of my computer, which is likely! :)

Hi Atul, As mentioned below to Michael and Guillermo, look out for these being added when our CPA review has been finalized. Thanks, Pete